Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial

Published:2024-02 Issue:2 Volume:12 Page:e257-e270
ISSN:2214-109X
Container-title:The Lancet Global Health
language:en
Short-container-title:The Lancet Global Health

Author:

Tricou Vianney,Yu Delia,Reynales Humberto,Biswal Shibadas,Saez-Llorens Xavier,Sirivichayakul Chukiat,Lopez Pio,Borja-Tabora Charissa,Bravo Lulu,Kosalaraksa Pope,Vargas Luis Martinez,Alera Maria Theresa,Rivera Luis,Watanaveeradej Veerachai,Dietze Reynaldo,Fernando LakKumar,Wickramasinghe V Pujitha,Moreira Edson Duarte,Fernando Asvini D,Gunasekera Dulanie,Luz Kleber,Oliveira Ana Lucia,Tuboi Suely,Escudero Ian,Hutagalung Yanee,Lloyd Eric,Rauscher Martina,Zent Olaf,Folschweiller Nicolas,LeFevre Inge,Espinoza Felix,Wallace Derek

Publisher

Elsevier BV

Subject

General Medicine

Reference33 articles.

1. Projecting the risk of mosquito-borne diseases in a warmer and more populated world: a multi-model, multi-scenario intercomparison modelling study;Colón-González;Lancet Planet Health,2021

2. Dengue: a continuing global threat.;Guzman;Nat Rev Microbiol,2010

3. Measuring the effects of COVID-19-related disruption on dengue transmission in southeast Asia and Latin America: a statistical modelling study;Chen;Lancet Infect Dis,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TAK-003 dengue vaccine as a new tool to mitigate dengue in countries with a high disease burden;The Lancet Global Health;2024-02